Advanced Bionics, a subsidiary of Switzerland-based Sonova Group, has received US Food and Drug Administration approval for commercialisation of its new Naída CI Q70 (Naída CI) sound processor.
Advanced Bionics and Phonak have partnered to develop Naída CI, an advanced behind-the-ear sound processor in the market.
With a chic, lightweight design, Naída CI features the most advanced cochlear implant technology with state-of-the-art Phonak technology for high-performance hearing.
Advanced Bionics president Sonova Medical Division group vice-president Hansjuerg Emch said with Naída CI, the company has delivered a quantum leap forward in performance and wireless connectivity in a small, attractive package.
"If you use Phonak products and get a cochlear implant from AB, you now have the opportunity to enjoy many of the same Phonak features and accessories," Emch said.
The Phonak UltraZoom feature in combination with Advanced Bionics’s ClearVoice technology yields 55% improvement in speech recognition in noise.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Naída CI features an instyle design and is 40% smaller than the previous behind-the-ear sound processors. It offers a full performance package with ClearVoice, AutoSound, HiRes Fidelity 120 and HiRes Optima sound processing technologies.
In addition, it offers 100% wireless connectivity to mobile phones, bluetooth-enabled products, and countless other devices.
Earlier this year, Naída CI was cleared for distribution in Europe, Canada and several other countries in the world.
According to GlobalData estimates, ENT Devices market in the US, which was valued at $3.17bn in 2012 is expected to grow at a CAGR of 7.5% to reach $5.25bn by 2019.